Anakinra is a recombinant interleukin (IL)-1 receptor antagonistusedforseveralinflammatoryconditionsincludingsystemicjuvenileidiopathicarthritis,recurrentpericarditis,andfamilialMediterraneanfever (FMF). Its efficacy in blocking IL-1 and its manageable safetyprofilesupportitsusealsoinotherconditions,suchassepsis,acutemyocardialinfarction,andCOVID-19
IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia / Naviglio, S., Zanella, G., Verzegnassi, F., Kiren, V., Giurici, N., Sieni, E., Coniglio, M.L., Valencic, E., Tommasini, A., Rabusin, M.. - In: PEDIATRIC BLOOD & CANCER. - ISSN 1545-5009. - ELETTRONICO. - 69:3(2022), pp. e29404."-"-e29404."-". [10.1002/pbc.29404]
IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia
Naviglio S.;Zanella G.
;Verzegnassi F.;Kiren V.;Giurici N.;Valencic E.;Tommasini A.;Rabusin M.
2022-01-01
Abstract
Anakinra is a recombinant interleukin (IL)-1 receptor antagonistusedforseveralinflammatoryconditionsincludingsystemicjuvenileidiopathicarthritis,recurrentpericarditis,andfamilialMediterraneanfever (FMF). Its efficacy in blocking IL-1 and its manageable safetyprofilesupportitsusealsoinotherconditions,suchassepsis,acutemyocardialinfarction,andCOVID-19| File | Dimensione | Formato | |
|---|---|---|---|
|
Pediatric Blood Cancer - 2021 - Naviglio - IL‐1 blockade with anakinra for severe inflammatory symptoms during.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
321.94 kB
Formato
Adobe PDF
|
321.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
3015300_Pediatric Blood Cancer - 2021 - Naviglio - IL‐1 blockade with anakinra for severe inflammatory symptoms during-Post_print.pdf
Open Access dal 10/10/2022
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Digital Rights Management non definito
Dimensione
874.09 kB
Formato
Adobe PDF
|
874.09 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
